Analyst firms · Robert W. Baird · AMLX

Robert W. Baird AMLX price target and rating history

Amylyx Pharmaceuticals Inc. (AMLX) · Health Care

Robert W. Baird rates Amylyx Pharmaceuticals Inc. (AMLX) Outperform with a $11 price target, as of its latest action on Nov 18, 2024. It has published 3 rating actions on AMLX since January 2024, including 1 upgrade and 1 downgrade.

Current rating
Outperform
Price target
$11
Median target, all firms
Too few
Actions on AMLX
3

Robert W. Baird price target on AMLX

$37$21$420252026
Robert W. Baird price target on AMLX, each point a stated target, January 2024 to November 2024.

Every Robert W. Baird rating on AMLX

Questions about Robert W. Baird and AMLX

What is Robert W. Baird's price target for AMLX?
Robert W. Baird's latest stated price target for Amylyx Pharmaceuticals Inc. (AMLX) is $11, from its action on Nov 18, 2024.
What is Robert W. Baird's rating on AMLX?
Robert W. Baird rates AMLX Outperform, a bullish rating, as of Nov 18, 2024.
When did Robert W. Baird last change its view on AMLX?
On Nov 18, 2024, Robert W. Baird upgrades to Outperform from Neutral, price target $3 to $11.

More AMLX rating histories

All Robert W. Baird ratingsAMLX news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.